Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Mono Pharmacare Ltd is a below average quality company.
The key valuation ratios of Mono Pharmacare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Mono Pharmacare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'23 | TTM | ||
|---|---|---|---|
| ROCE % ⓘ | 3.1% | - | |
| Value Creation Index ⓘ | -0.8 | - | |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||
| Sales ⓘ | 13.9 | 0 | |
| Sales YoY Gr. | - | - | |
| Adj EPS ⓘ | 0.4 | 0 | |
| YoY Gr. | - | - | |
| BVPS (₹) ⓘ | 10.8 | 16 | |
| Adj Net Profit ⓘ | 0.5 | 0 | |
| Cash Flow from Ops. ⓘ | -13.5 | - | |
| Debt/CF from Ops. ⓘ | -0.9 | - | |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | NA | NA | ||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||
| BVPSⓘ | NA | NA | NA | NA | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'23 | TTM | |
|---|---|---|
| Return on Equity % ⓘ | 4.1 | 0 |
| Op. Profit Mgn % ⓘ | 6.3 | NAN |
| Net Profit Mgn % ⓘ | 3.9 | NAN |
| Debt to Equity ⓘ | 0.9 | - |
| Working Cap Days ⓘ | 0 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 0 |
No data to display
Return on Equity has declined versus last 3 years average to 0.00%
Sales growth has been subdued in last 3 years 0.00%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0 | 0 |
| TTM Sales (₹ Cr.) | 0 | 0 |
| BVPS (₹.) ⓘ | 16 | 10 |
| Reserves (₹ Cr.) ⓘ | 11 | - |
| P/BV ⓘ | 2.78 | 4.45 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 78.5 |
| Equity (₹ Cr.) | 17.7 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 77.6 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'23 |
|---|---|
| Sales | 13.92 |
| Operating Expenses ⓘ | 13.05 |
| Manufacturing Costs | 0.01 |
| Material Costs | 11.88 |
| Employee Cost | 0.50 |
| Other Costs ⓘ | 0.65 |
| Operating Profit ⓘ | 0.87 |
| Operating Profit Margin (%) | 6.2% |
| Other Income ⓘ | 0.20 |
| Interest ⓘ | 0.38 |
| Depreciation ⓘ | 0.02 |
| Exceptional Items ⓘ | 0 |
| Profit Before Tax ⓘ | 0.67 |
| Tax ⓘ | 0.12 |
| Profit After Tax | 0.54 |
| PAT Margin (%) | 3.9% |
| Adjusted EPS (₹) | 0.4 |
| Dividend Payout Ratio (%) | 0% |
| PARTICULARS | Mar'23 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 13.40 | |||||||||
| Share Capital ⓘ | 12.37 | |||||||||
| Reserves ⓘ | 1.03 | |||||||||
| Minority Interest | 0 | |||||||||
| Debt | 12.51 | |||||||||
| Long Term Debt | 3.43 | |||||||||
| Short Term Debt | 9.07 | |||||||||
| Trade Payables | 2.09 | |||||||||
| Others Liabilities ⓘ | 1.02 | |||||||||
| Total Liabilities ⓘ | 29.01 | |||||||||
Fixed Assets | ||||||||||
| Gross Block | 0.21 | |||||||||
| Accumulated Depreciation | 0.02 | |||||||||
| Net Fixed Assetsⓘ | 0.19 | |||||||||
| CWIP ⓘ | 0 | |||||||||
| Investmentsⓘ | 1.97 | |||||||||
| Inventories | 15.18 | |||||||||
| Trade Receivables | 8.08 | |||||||||
| Cash Equivalents | 0.23 | |||||||||
| Others Assetsⓘ | 3.36 | |||||||||
| Total Assets ⓘ | 29.01 | |||||||||
| PARTICULARS | Mar'23 |
|---|---|
| Cash Flow From Operating Activity ⓘ | -13.49 |
| PBT ⓘ | 0.67 |
| Adjustment ⓘ | 0.40 |
| Changes in Working Capital ⓘ | -14.56 |
| Tax Paid ⓘ | 0 |
| Cash Flow From Investing Activity ⓘ | -2.18 |
| Capex | -0.21 |
| Net Investments | -1.97 |
| Others ⓘ | 0 |
| Cash Flow From Financing Activityⓘ | 15.90 |
| Net Proceeds from Shares ⓘ | 12.86 |
| Net Proceeds from Borrowing ⓘ | 3.43 |
| Interest Paid ⓘ | -0.38 |
| Dividend Paid ⓘ | 0 |
| Others ⓘ | -0.01 |
| Net Cash Flow ⓘ | 0.23 |
| PARTICULARS | Mar'23 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 4.04 | |||||||||
| ROCE (%) | 4.03 | |||||||||
| Asset Turnover Ratio | 0.48 | |||||||||
| PAT to CFO Conversion(x) | -24.98 | Working Capital Days | ||||||||
| Receivable Days | 212 | |||||||||
| Inventory Days | 398 | |||||||||
| Payable Days | 64 | |||||||||
Mono Pharmacare was originally formed as a partnership firm in the name and style of ‘M/s. Mono Chemist’ through partnership deed dated May 06, 1994. Promoters of its company Panilam Lakhatariya and Supal Lakhatariya joined the partnership firm on May 10, 2018, as partners of the firm. Further, its Promoters acquired 100% ownership of the partnership firm on July 25, 2019. Further, new partners i.e. Shivlal Gandalal Lakhatariya, Shardaben Shivlal Lakhatariya, Shivam Parag Chauhan, Archit Suhasbhai Shah and Pallaviben Suhasbhai Shah were added pursuant to deed of admission dated June 18, 2022. The partnership firm was then converted into Public Limited company under part I (Chapter XXI) of the Companies Act, 2013 in the name and style of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
Mono Pharmacare is engaged in the business of marketing of pharmaceutical products and also, it is distributors of various pharmaceutical companies. It works with various contract manufacturers who manufacture pharmaceutical products on its behalf based on compositions given by it and subsequently it sells those products under its brand ‘DLS Export’. It is also distributors to various pharmaceutical companies. As on February 28, 2023, it is dealing with (distributors and stockists) many pharmaceutical companies and also, it is connected with many customers/vendors who are a mix of retail pharmacy stores as well as wholesalers. It promoters have a combined experience of more than a decade in the pharmaceutical industry. Its Promoters have been the pillars of its Company’s growth since beginning and with their enriching experience and progressive thinking, it aims to continue to grow in the pharmaceutical industry.
The company is a distributor and supplier of a wide array of Pharmaceuticals products and medicines. As a leading provider in the pharma industry, it is committed to delivering high-quality products and services that meet people’s healthcare needs. With its expertise and dedication. The company offers Health Care products, Antibiotic medicines, Cough Cold Anti Allergic medicines, Antifungal medicines, Nutraceutical medicines, Analgesic & Antipyretic medicines, Antacid & Antiemetics medicines, Cardiac-Diabetic medicines, and cosmocare products. At Mono Pharmacare, it prioritize quality in every step of the pharmaceutical solution process. It understands that health is of utmost importance, and therefore, it adheres to strict quality control measures to ensure that its products meet the highest standards. From sourcing raw materials to conducting rigorous testing, it leaves no stone unturned to deliver safe and effective medications.
Business area of the company
The company is engaged in the business of marketing of pharmaceutical products and also, it is distributors of various pharmaceutical companies.
Products of the company
Awards, certifications & recognitions
History and milestone
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
